|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | PI3K-AKT-mTOR signaling in prostate cancer progression and androgen deprivation therapy resistance显示文摘前列腺癌症(PCa ) 是在在世界上的人之中的第二很普通的恶意。阉割抵抗的前列腺癌症(CRPC ) 是疾病的致命的形式,它在抵抗之上发展首先衬里雄激素剥夺治疗(ADT ) 。新兴的证据为在 CRPC 的发展和维护表明轴的 PI3K-AKT-mTOR 表明一个关键角色。这条小径,是在先进 PCas 的多数的 deregulated,与象蛋白质合成,增长,幸存,新陈代谢和区别那样的下游地细胞的过程为生长信号的集成用作批评连结,因此提供机制让癌症细胞克服压力与雄激素剥夺联系了。而且,现出症状之前的潜的研究阐明了在发信号的 PI3K-AKT-mTOR 和雄激素受体(AR ) 之间的一个直接连接削减,在 ADT 抵抗的发展期间揭示在这些小径之间的动态相互影响。因此,为 PI3K 小径的很多个新奇禁止者的继续的临床的发展有一个清楚的基本原理,它提供堵住 CRPC 生长和幸存的潜力。在这评论,我们将在 PCa 前进和阉割抵抗探索 PI3K-AKT-mTOR 小径的关联以便在先进 PCa 通知临床的发展特定的小径禁止者。另外,我们将在我们的临床的知识加亮当前的缺乏,最尤其是对能精确地为对 PI3K 小径禁止者的反应预言的 biomarkers 的需要。 | Merritt P Edlind Andrew C Hsieh | 2014 | Asian Journal of Andrology2014，16，3： | 20 |
| 2 | Continuous Cerebral Blood Flow Autoregulation Monitoring in Patients Undergoing Liver Transplantation显示文摘 | Yueying Zheng April Villamayor William Merritt Aliaksei Pustavoitau Asad Latif Ramola Bhambhani Steve Frank Ahmet Gurakar Andrew Singer Andrew Cameron Robert Stevens Charles Hogue | 2012 | Neurocritical Care2012，，1： | 1 |
| 3 | Soil conditioning for clay soils显示文摘 | Mair Robert Merritt Andrew | 2003 | Tunnels and Tunnelling International2003，，： | 1 |
| 4 | Liver transplantation in patients with severe portopulmonary hypertension treated with preoperative chronic intravenous epoprostenol显示文摘 | Henkie P. Tan Jay S. Markowitz Robert A. Montgomery William T. Merritt Andrew S. Klein Paul J. Thuluvath F.Fred Poordad Warren R. Maley Bradford Winters Seda B. Akinci Sean P. Gaine | 2001 | Liver Transplantation2001，，8： | 1 |
| 5 | Rationale and Treatment ofMuhiple-Ligament Injured Knees: The Seattle Perspective 显示文摘 | Andrew L Merritt MD Christopher J | 2011 | Oper Tech Sports Med2011，，19： | 1 |
| 6 | Better Than You Think—Appropriate Use of Implantable Cardioverter-Defi brillators at a Single Academic Center:A Retrospective Review显示文摘Background:Implantable cardioverter-defi brillators(ICDs)can be life-saving devices,although they are expensive and may cause complications.In 2013,several professional societies published joint appropriate use criteria(AUC)assessing indications for ICD implantation.Data evaluating the clinical application of AUC are limited.Previous registry-based studies estimated that 22.5%of primary prevention ICD implantations were“non-evidence-based”implantations.On the basis of AUC,we aimed to determine the prevalence of“rarely appropriate”ICD implantation at our institution for comparison with previous estimates.Methods:We reviewed 286 patients who underwent ICD implantation between 2013 and 2016.Appropriateness of each ICD implantation was assessed by independent review and rated on the basis of AUC.Results:Of 286 ICD implantations,two independent reviewers found that 89.5%and 89.2%,respectively,were appropriate,5.6%and 7.3%may be appropriate,and 1.8%and 2.1%were rarely appropriate.No AUC indication was found for 3.5%and 3.4%of ICD implantations,respectively.Secondary prevention ICD implantations were more likely rarely appropriate(2.6%vs.1.2%and 3.6%vs.1.1%)or unrated(6.0%vs.1.2%and 2.7%vs.0.6%).The reviewers found 3.5%and 3.4%of ICD implantations,respectively,were non-evidence-based implantations.The difference in rates between reviewers was not statistically signifi cant.Conclusion:Compared with prior reports,our prevalence of rarely appropriate ICD implantation was very low.The high appropriate use rate could be explained by the fact that AUC are based on current clinical practice.The AUC could benefi t from additional secondary prevention indications.Most importantly,clinical judgement and individualized care should determine which patients receive ICDs irrespective of guidelines or criteria. | Nikhil H.Shah Steven J.Ross Steve A.Noutong Njapo Justin Merritt Andrew Kolarich Michael Kaufmann William M.Miles David E.Winchester Thomas A.Burkart Matthew McKillop | 2021 | Cardiovascular Innovations and Applications2021，，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员